Contrasting of Outlook Therapeutics Inc. (OTLK) and Cara Therapeutics Inc. (NASDAQ:CARA)

Outlook Therapeutics Inc. (NASDAQ:OTLK) and Cara Therapeutics Inc. (NASDAQ:CARA) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Outlook Therapeutics Inc. 3.25M 18.58 42.92M -7.16 0.00
Cara Therapeutics Inc. 17.85M 43.13 79.21M -2.10 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Outlook Therapeutics Inc. and Cara Therapeutics Inc.

Profitability

Table 2 provides us the return on equity, net margins and return on assets of both companies.

Net Margins Return on Equity Return on Assets
Outlook Therapeutics Inc. -1,320.62% 158.6% -156.3%
Cara Therapeutics Inc. -443.75% -67.3% -44.4%

Liquidity

Outlook Therapeutics Inc.’s Current Ratio and Quick Ratio are 0.1 and 0.1 respectively. The Current Ratio and Quick Ratio of its competitor Cara Therapeutics Inc. are 3.4 and 3.4 respectively. Cara Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Outlook Therapeutics Inc.

Analyst Ratings

Ratings and Recommendations for Outlook Therapeutics Inc. and Cara Therapeutics Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Outlook Therapeutics Inc. 0 0 0 0.00
Cara Therapeutics Inc. 0 1 6 2.86

On the other hand, Cara Therapeutics Inc.’s potential upside is 33.61% and its consensus target price is $25.88.

Insider & Institutional Ownership

The shares of both Outlook Therapeutics Inc. and Cara Therapeutics Inc. are owned by institutional investors at 2.5% and 60.7% respectively. About 4.2% of Outlook Therapeutics Inc.’s share are owned by insiders. Competitively, insiders own roughly 2.7% of Cara Therapeutics Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Outlook Therapeutics Inc. -28.87% -41.64% -88.95% -87.15% -88.39% -77.24%
Cara Therapeutics Inc. -2.2% -3.76% 11.84% -4.88% 47.79% 43.92%

For the past year Outlook Therapeutics Inc. has -77.24% weaker performance while Cara Therapeutics Inc. has 43.92% stronger performance.

Summary

On 9 of the 11 factors Cara Therapeutics Inc. beats Outlook Therapeutics Inc.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body's peripheral nervous system. The companyÂ’s lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.